Appili announces dosing of first patient in phase 3 Covid-19 trial
PRA Health Sciences, a clinical research organisation (CRO) selected by Appili, will conduct the trial at 47 outpatient sites. Avigan, which is an antiviral in oral tablet form
PRISM BioLab has formed a collaboration with Receptor.AI to integrate AI and physics-guided technologies in the discovery of orally available small molecules.
Bamlanivimab recently received emergency use authorization for the treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.
SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases. “This transaction will help
The FDA grants Breakthrough Therapy designation to new medicines that are intended to treat a serious condition and where clinical evidence indicates that the drug may demonstrate substantial